Association of soluble TREM-like transcript-1 with clinical features and patient reported outcomes in systemic lupus erythematosus

Abstract

ObjectiveThe soluble triggering receptor expressed on myeloid cells (TREM-1)-like transcript 1 (sTLT-1) has a modulatory effect on the activation of TREM-1. We compared plasma sTLT-1 levels between patients with systemic lupus erythematosus (SLE) and healthy individuals and determined the association between sTLT-1 levels and clinical features and patient-reported outcomes (PROs) among patients with lupus.MethodsAn unmatched case-control study was conducted in 46 patients with SLE and 28 healthy subjects. sTLT-1 plasma levels were determined using enzyme-linked immunosorbent assay. Demographic factors, SLE manifestations, comorbidities, pharmacologic profile, disease activity (per SLAM-R), damage accrual, and PROs (as per Lupus Patient-Reported Outcome [LupusPRO]) were studied.ResultsPatients with SLE were found to have lower sTLT-1 levels compared with healthy individuals (9.0±7.2 vs. 18.6±22.3 pg/mL, p=0.008). Among patients with SLE, higher sTLT-1 levels were found in those taking corticosteroids (11.1±8.8 vs. 6.9±4.6 pg/mL, p=0.014). Significant correlations were found for the cognition (r=−0.442, p=0.027) and desires/goals (r=0.435, p=0.030) domains of LupusPRO. A tendency was observed between sTLT-1 levels and the SLAM-R (r=−0.278, p=0.064) and the lupus symptoms (r=−0.388, p=0.055) and physical health (r=−0.382, p=0.060) domains of LupusPRO.ConclusionCompared with healthy individuals, sTLT-1 levels were significantly lower in patients with SLE. Among patients with SLE, correlations were observed for some domains of LupusPRO. Given that sTLT-1 has anti-inflammatory properties, the deficiency of this protein could play an important role in the pathogenesis of SLE.

DIA proteomics analysis through serum profiles reveals the significant proteins as candidate biomarkers in women with PCOS

“…Based on the critical role in immune, inflammation and platelets, previous studies of TLT-1 are mainly focused on these associated diseases. In patients with systemic lupus erythematosus, the soluble TLT-1 levels were significantly lower than healthy individuals [ 30 ]. In a model of acute lung injury, results showed that infusion of sTLT-1 restored normal fibrinogen deposition and alleviated pulmonary hemorrhage by 40% and tissue damage by 25% [ 31 ].…”

Anti-Triggering Receptor Expressed on Myeloid Cells-Like Transcript-1 Antibodies in Systemic Lupus Erythematosus

“… 1 Previously, we reported that patients with systemic lupus erythematosus (SLE) had significantly lower levels of soluble TLT-1 (sTLT-1) when compared to healthy individuals. 2 Thus, we thought to determine if lower sTLT-1 levels are associated with the presence of anti-TLT-1 antibodies in SLE patients and if anti-TLT-1 antibodies are linked with SLE clinical features.…”

“…Anti-TLT-1 antibodies were measured by enzyme-linked immunosorbent assay (ELISA) from stored plasma samples of the same SLE patients and healthy individuals that we previously reported and using sTLT-1 developed in-house. 1 , 2 The ELISA was developed according to Pierangeli and Harris. 3 Among SLE patients, we examined associations of anti-TLT-1 antibodies with demographic factors, SLE manifestations (per 1997 American College of Rheumatology (ACR) modified classification criteria), pharmacologic profile, comorbidities, disease activity (per the revised SLE activity measure (SLAM-R)), and the disease damage (per Systemic Lupus International Collaborating Clinics Damage Index).…”